Androgen Receptor Expression in Triple Negative Breast Cancer - Study from a Tertiary Health Care Center in South India

Abstract

Background: The treatment of breast cancer is based on a multi-modality approach. Analysis of the hormone receptor has been accepted as a standard procedure, in the routine management of breast cancer patients. Triple negative breast cancers (TNBCs) are those which are negative for expression of all three markers, i.e., estrogen receptor, progesterone receptor (PR), and human epidermal growth factor receptor. High expression of Ki-67, a proliferation index, has been associated with a worse prognosis in TNBC. TN cancers are aggressive in nature as they do not respond to routine targeted therapy. The role of the androgen receptor (AR) in breast carcinomas is important as AR has been suggested as a potential therapeutic target. We did this study to assess AR immunoreactivity in TNBCs and correlate with Ki-67 index. Materials and Methods: In this study group, there were 45 cases of TN invasive breast carcinomas. These tumors were analyzed with respect to AR and Ki-67 index. Results: Of 45 TN breast carcinomas analyzed, 42 were infiltrating duct cell carcinoma (IDCC) of not otherwise specified type. There were one medullary and two metaplastic carcinomas. The median age was 46 years. AR was positive in 20% (9/45) of cases. All the AR positive cases were an IDCC (nos). Out of the nine AR positive cases, six showed positivity for Ki-67. The statistical analysis using Pearson's Chi-squared method did not reveal any correlation between AR and Ki-67 index (P = 0.574). Conclusion: Although our study did not reveal any statistically significant correlation between AR and Ki-67 index, assessment of AR status in TNBC patients is desirable as it may help to develop a targeted therapy in future in these aggressive cancers.

Keywords

Androgen receptor - breast cancer - Ki-67 index - triple negative breast cancer

Publication History

Article published online:
23 June 2021

• References

• 1 Qi JP, Yang YL, Zhu H, Wang J, Jia Y, Liu N. et al. Expression of the androgen receptor and its correlation with molecular subtypes in 980 Chinese breast cancer patients. Breast Cancer (Auckl) 2012; 6: 1-8
• 2 Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C. et al. GLOBOCAN 2012 v 1.0, Cancer incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://www.globocan,iarc.fr. [Last accessed on 2017 Oct 02]
• 3 Sharma M, Sharma JD, Sarma A, Ahmed S, Kataki AC, Saxena R. et al. Triple negative breast cancer in people of North East India: Critical insights gained at a regional cancer centre. Asian Pac J Cancer Prev 2014; 15: 4507-11
• 4 Nahleh Z. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: An unchartered territory. Future Oncol 2008; 4: 15-21
• 5 Sutton LM, Cao D, Sarode V, Molberg KH, Torgbe K, Haley B. et al. Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. Am J Clin Pathol 2012; 138: 511-6
• 6 Chen J, Zhang X, Tian R, Liu Y, Dong HM, Guo RF. et al. Expression of androgen receptor in breast carcinoma and its relationship with estrogen receptor, progesterone receptor and HER2 status. Zhonghua Bing Li Xue Za Zhi 2010; 39: 743-6
• 7 National Cancer Registry Programme, Indian Council of Medical Research. Leading sites of cancer. In: Consolidated Report of Population Based Cancer Registries 2001-2004, Incidence and Distribution of Cancer. Bangalore: Coordinating Unit, National Cancer Registry Programme (ICMR); 2006.p.8-30
• 8 Patnayak R, Jena A, Rukmangadha N, Chowhan AK, Sambasivaiah K, Phaneendra BV. et al. Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience. Indian J Med Paediatr Oncol 2015; 36: 117-22
• 9 McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Sinha S. et al. Androgen receptor-positive triple negative breast cancer: A unique breast cancer subtype. Ann Surg Oncol 2014; 21: 361-7
• 10 Lim E, Ni M, Cao S, Hazra A, Tamimi RM, Brown M. et al. Importance of breast cancer subtype in the development of androgen receptor directed therapy. Curr Breast Cancer Rep 2014; 6: 71-8
• 11 Li S, Han B, Liu G, Li S, Ouellet J, Labrie F. et al. Immunocytochemical localization of sex steroid hormone receptors in normal human mammary gland. J Histochem Cytochem 2010; 58: 509-15
• 12 Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W. et al. Androgen receptors frequently are expressed in breast carcinomas: Potential relevance to new therapeutic strategies. Cancer 2003; 98: 703-11
• 13 Gucalp A, Traina TA. Triple-negative breast cancer: Role of the androgen receptor. Cancer J 2010; 16: 62-5
• 14 Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: Results from the nurses' health study. Mod Pathol 2011; 24: 924-31
• 15 Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA. et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 2013; 19: 5505-12